Treatment of an Acute Promyelocytic Leukemia Relapse Using Arsenic Trioxide and All-Trans-Retinoic in a 6-Year-Old Child

REFERENCES

• Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematologica. 2008;119:73–82.
   PubMed Web of Science ®Google Scholar
• Yoo ES. Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr. 2011;54:95–105.
   PubMedGoogle Scholar
• Lengfelder E, Hofmann W-K, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26:433–442.
   PubMed Web of Science ®Google Scholar
• Zhang X-W, Yan X-J, Zhou Z-R, Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (New York, N.Y.). 2010;328:240–243.
   PubMed Web of Science ®Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood . 2006;107:3469–3473.
   PubMed Web of Science ®Google Scholar
• George B, Mathews V, Poonkuzhali B, Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18: 1587–1590.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu X, Zou Y, Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. Int J Hematol. 2011;93:199–205.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y, Li J, Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115:1697–702.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao H, Zhu X, Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience. Pediatr Blood Cancer. 2008;51:210–215.
   PubMedGoogle Scholar
• Beccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031–1043.
   Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, Retinoic acid and arsenic trioxide for acutepromyelocytic leukemia. N Engl J Med. 2013;369:111–121.
   PubMed Web of Science ®Google Scholar
• Huang H, Qin Y, Xu R, Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leukemia Res. 2012;36:841–845.
   Google Scholar
• Ebinger M, Schwarze CP, Feuchtinger T, Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Pediatr Hematol Oncol. 2011;28:334–337.
   PubMed Web of Science ®Google Scholar
• Fox E, Razzouk BI, Widemann BC, Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008;111:566–573.
   PubMed Web of Science ®Google Scholar
• Au WY, Li C, Lee V, Oral Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia in Pediatric Patients. Pediatr Blood Cancer. 2012;58:630–632.
   PubMed Web of Science ®Google Scholar
• Visani G, Piccaluga PP, Martinelli G, Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease. Haematologica. 2003;88: ELT15.
   Google Scholar
• Jurcic J-G, Nimer S-D, Scheinberg D-A, Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001;98: 2651–2656.
   PubMed Web of Science ®Google Scholar
• Zhou G-B, Zhang J, Wang Z-Y, Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philosophical transactions of the Royal Society of London Series B, Biological Sci. 2007;362:959–971.
   Google Scholar
• Wang H, Chen X, Wang B, The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leukemia Res. 2001;35:1170–1177.
   Google Scholar
• Soignet SL, Frankel SR, Douer D, United States Multicenter Study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852–3860.
   PubMed Web of Science ®Google Scholar
• Breccia M, Lo-Coco F. Arsenic trioxide for managementof acute promyelocytic leukemia: current evidence on its role in front-line therap and recurrent disease. Expert Opin Pharmacother. 2012;13(7):1031–1043.
   PubMed Web of Science ®Google Scholar
• Bally C, Fadlallah J, Leverger G, Outcome of acute promyelocytic leukemia in children and adolescents: an analysis in two consecutive trials of The European APL Group. J Clin Oncol. 30:1641–1646.
   Google Scholar